Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMBI-AD adjuvant dabrafenib + trametinib in high-risk BRAF V600 melanoma
jRCT2080222458Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2014
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in cutaneous melanoma (CM) and melanoma comparing Dabrafenib + trametinib with Placebo (2 arms). Started Apr 2014; status: completed.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
cutaneous melanoma (CM)melanoma
Beyond the preview
Go deeper on jRCT2080222458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222458.